Compare · CI vs MDXH
CI vs MDXH
Side-by-side comparison of The Cigna Group (CI) and MDxHealth SA (MDXH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CI and MDXH operate in Medical Specialities (Health Care), so they compete in similar markets.
- CI is the larger of the two at $73.81B, about 980.6x MDXH ($75.3M).
- Over the past year, CI is down 6.9% and MDXH is down 78.3% - CI leads by 71.3 points.
- MDXH has been more active in the news (9 items in the past 4 weeks vs 7 for CI).
- CI has more recent analyst coverage (25 ratings vs 5 for MDXH).
- Company
- The Cigna Group
- MDxHealth SA
- Price
- $279.37-0.35%
- $0.79+5.09%
- Market cap
- $73.81B
- $75.3M
- 1M return
- -3.98%
- +92.16%
- 1Y return
- -6.93%
- -78.27%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 7
- 9
- Recent ratings
- 25
- 5
The Cigna Group
Cigna Corporation provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company's U.S. Medical segment offers commercial products and services, including medical, pharmacy, behavioral health, dental, vision, health advocacy programs, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as Medicaid plans; and individual health insurance plans to on and off the public exchanges. Its International Markets segment offers health coverage, hospitalization, dental, critical illness, personal accident, term life, medical cost containment, and variable universal life products, as well as health care benefits to mobile employees of multinational organizations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.
MDxHealth SA
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
Latest CI
- SEC Form 4 filed by Officer Holgerson Bryan
- Officer Jones Nicole S sold $748,516 worth of shares (2,677 units at $279.61) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 25,880 units (SEC Form 4)
- SEC Form 144 filed by The Cigna Group
- Officer Jones Nicole S exercised 15,346 shares at a strike of $192.02 and sold $5,369,584 worth of shares (19,436 units at $276.27) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 28,557 units (SEC Form 4)
- SEC Form 144 filed by The Cigna Group
- The Cigna Group downgraded by Jefferies with a new price target
- The Cigna Group downgraded by Raymond James with a new price target
- SEC Form 10-Q filed by The Cigna Group
- The Cigna Group filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- The Cigna Group Reports Strong Second Quarter 2026 Results, Raises 2026 Outlook
Latest MDXH
- Amendment: SEC Form SCHEDULE 13G/A filed by MDxHealth SA
- Director Mvm Partners, Llc bought $1,000,000 worth of Ordinary Shares (2,202,643 units at $0.45) (SEC Form 4)
- SEC Form SCHEDULE 13D filed by MDxHealth SA
- These Biotech Breakouts and Squeeze Setups Could Be Just Getting Started
- SEC Form 6-K filed by MDxHealth SA
- SEC Form 424B5 filed by MDxHealth SA
- SEC Form 6-K filed by MDxHealth SA
- Mdxhealth Reports Second Quarter 2026 Financial Results
- Amendment: SEC Form SCHEDULE 13G/A filed by MDxHealth SA
- Mdxhealth to Release Second Quarter 2026 Financial Results on August 13